{"id":"W2159370562","doi":"10.1093/eurheartj/ehr334","title":"RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome","year":2011,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"Servier; Astellas Pharma","keywords":"Medicine; Tolerability; Placebo; Acute coronary syndrome; Randomized controlled trial; Double blind; Internal medicine; Adverse effect; Myocardial infarction; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003236434,0.0002161083,0.001255314,0.00009363356,0.0002547154,0.00003126025,0.0002122122,0.00005253015,0.000180666],"category_scores_gemma":[0.0004900122,0.0001068314,0.001213129,0.0001795076,0.0002147802,0.0001655324,0.0002278235,0.0003867093,0.000004773907],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004037025,"about_ca_system_score_gemma":0.0001112413,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001061866,"about_ca_topic_score_gemma":0.000002210174,"domain_scores_codex":[0.9968553,0.0009910819,0.001170262,0.0001986371,0.0005616126,0.0002231074],"domain_scores_gemma":[0.99838,0.0003656718,0.0006336245,0.0003895873,0.000102473,0.0001286361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9428293,0.00005979557,0.05441261,0.00002202162,0.0008639163,0.00002097714,0.0006417944,0.000004698609,0.0008712479,0.00006215798,0.00007918089,0.0001323316],"study_design_scores_gemma":[0.8175345,0.0003446567,0.1800264,0.0001276771,0.0008364224,0.0002618715,0.00007258935,0.00003365529,0.0001727316,0.00001772115,0.0004747076,0.00009706007],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911578,0.00008704369,0.0001388715,0.001150024,0.001759066,0.003580994,0.000009718265,0.00001689164,0.002099635],"genre_scores_gemma":[0.9980195,0.00002330586,0.0003556922,0.0001120413,0.000388286,0.000002459839,0.000001454496,0.0000293518,0.001067965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1256138,"threshold_uncertainty_score":0.4356458,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1060709866182456,"score_gpt":0.3253483990563421,"score_spread":0.2192774124380965,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}